Literature DB >> 27776749

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Naomi P Visanji1, Jonathan M Brotchie2, Lorraine V Kalia3, James B Koprich2, Anurag Tandon4, Joel C Watts5, Anthony E Lang3.   

Abstract

In recent years, a new generation of animal models of Parkinson's disease (PD) based on ectopic expression, overexpression, or intracerebral injection of the protein α-synuclein have emerged. Critically, these models develop inclusions of aggregated α-synuclein and/or α-synuclein-mediated neuronal loss replicating the defining pathological hallmarks of PD and driving significant advances in the understanding of the pathogenic mechanisms underpinning PD. Here, we provide a comprehensive review of this new generation of animal models of PD, ranging from invertebrate to rodent to nonhuman primate. We focus on their strengths and limitations with respect to their highly anticipated contribution to the further understanding of α-synuclein pathobiology and the future testing of novel disease-modifying therapeutics.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Parkinson's disease; alpha synuclein; animal models; drug development; prion; transgenic

Mesh:

Substances:

Year:  2016        PMID: 27776749     DOI: 10.1016/j.tins.2016.09.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  51 in total

1.  Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.

Authors:  Nahid Tayebi; Loukia Parisiadou; Bahafta Berhe; Ashley N Gonzalez; Jenny Serra-Vinardell; Raphael J Tamargo; Emerson Maniwang; Zachary Sorrentino; Hideji Fujiwara; Richard J Grey; Shahzeb Hassan; Yotam N Blech-Hermoni; Chuyu Chen; Ryan McGlinchey; Chrissy Makariou-Pikis; Mieu Brooks; Edward I Ginns; Daniel S Ory; Benoit I Giasson; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2017-11-21       Impact factor: 4.797

Review 2.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

3.  α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.

Authors:  Paul M Levine; Ana Galesic; Aaron T Balana; Anne-Laure Mahul-Mellier; Mariana X Navarro; Cesar A De Leon; Hilal A Lashuel; Matthew R Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-16       Impact factor: 11.205

4.  Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.

Authors:  Esteban Luna; Samantha C Decker; Dawn M Riddle; Anna Caputo; Bin Zhang; Tracy Cole; Carrie Caswell; Sharon X Xie; Virginia M Y Lee; Kelvin C Luk
Journal:  Acta Neuropathol       Date:  2018-03-03       Impact factor: 17.088

5.  An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease1.

Authors:  Velmarini Vasquez; Joy Mitra; George Perry; K S Rao; Muralidhar L Hegde
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

Review 7.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 8.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

9.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

Review 10.  Immune Signaling in Neurodegeneration.

Authors:  Timothy R Hammond; Samuel E Marsh; Beth Stevens
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.